Fenofibrat w leczeniu zaburzeń lipidowych — przegląd najnowszych doniesień

Abstract

Fenofibrate has been used for many years in the treatment of lipid disorders. Its efficacy and safety have been assessed in many studies, and the evidence base continues to expand with each passing year. To supplement the knowledge on the potential of the drug in the registration indications, this paper summarizes the latest reports. As in previously published studies, also in the current reports, the beneficial effect of fenofibrate on lipid values in patients with hypertriglyceridemia or mixed dyslipidaemia (including diabetic patients) is beyond doubt confirmed. Recent studies also increasingly raise the issue of the effect of fenofibrate on hard endpoints, important both from the patient’s and physician’s perspective. The identified scientific evidence supports the thesis that in patients with type 2 diabetes or metabolic syndrome, fenofibrate therapy reduces mortality and the risk of cardiovascular events. In addition, long-term maintenance of favourable therapeutic effects, even after treatment discontinuation, was observed, as well as signals indicating potential renoprotective activity of the drug. The latest reports also confirm previous observations, according to which fenofibrate therapy is generally well-tolerated and safe. Taking the above into account, it is reasonable for this drug to maintain its place in the modern treatment of lipid disorders.